Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dodel

Showing results (141-150 of 250) with videos related to

Pageof 25
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 8, 2015
Determinants of societal costs in Alzheimer's disease: GERAS study baseline resultsRichard Dodel, Mark Belger, Catherine Reed, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 20, 2018
Antidepressant medication in a German cohort of patients with Alzheimer's disease
Philipp Hessmann, Richard Dodel, Erika Baum, et al.
Journal of Alzheimer'S Disease : JAD|March 18, 2017
What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS StudyCatherine Reed, Michael Happich, Josep Maria Argimon, et al.
Muscle & Nerve|August 4, 2018
Costs of illness in chronic inflammatory demyelinating polyneuropathy in GermanyDavid Mengel, Linda Fraune, Norbert Sommer, et al.
Molecular Neurobiology|July 21, 2018
IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker DiseaseHuiying Gu, Yvonne Kirchhein, Timothy Zhu, et al.
Molecular Medicine (Cambridge, Mass.)|March 5, 2010
The role of macrophage migration inhibitory factor in Alzheimer's diseaseMichael Bacher, Oliver Deuster, Bayan Aljabari, et al.
Sleep|November 10, 2004
The socioeconomic impact of narcolepsyRichard Dodel, Helga Peter, Tobias Walbert, et al.
Journal of Neurology|December 1, 2009
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort studyYaroslav Winter, Sonja von Campenhausen, Julia Gasser, et al.
BMC Cancer|December 30, 2009
Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdownJörg Schrader, Oliver Deuster, Birgit Rinn, et al.
Neurology|December 21, 2012
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson diseaseDaniela Besong-Agbo, Elias Wolf, Frank Jessen, et al.
Pageof 25

Showing results (141-150 of 250) with videos related to

Sort By:
Pageof 25
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 8, 2015
Determinants of societal costs in Alzheimer's disease: GERAS study baseline resultsRichard Dodel, Mark Belger, Catherine Reed, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 20, 2018
Antidepressant medication in a German cohort of patients with Alzheimer's disease
Philipp Hessmann, Richard Dodel, Erika Baum, et al.
Journal of Alzheimer'S Disease : JAD|March 18, 2017
What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS StudyCatherine Reed, Michael Happich, Josep Maria Argimon, et al.
Muscle & Nerve|August 4, 2018
Costs of illness in chronic inflammatory demyelinating polyneuropathy in GermanyDavid Mengel, Linda Fraune, Norbert Sommer, et al.
Molecular Neurobiology|July 21, 2018
IVIG Delays Onset in a Mouse Model of Gerstmann-Sträussler-Scheinker DiseaseHuiying Gu, Yvonne Kirchhein, Timothy Zhu, et al.
Molecular Medicine (Cambridge, Mass.)|March 5, 2010
The role of macrophage migration inhibitory factor in Alzheimer's diseaseMichael Bacher, Oliver Deuster, Bayan Aljabari, et al.
Sleep|November 10, 2004
The socioeconomic impact of narcolepsyRichard Dodel, Helga Peter, Tobias Walbert, et al.
Journal of Neurology|December 1, 2009
Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort studyYaroslav Winter, Sonja von Campenhausen, Julia Gasser, et al.
BMC Cancer|December 30, 2009
Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdownJörg Schrader, Oliver Deuster, Birgit Rinn, et al.
Neurology|December 21, 2012
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson diseaseDaniela Besong-Agbo, Elias Wolf, Frank Jessen, et al.
Pageof 25